huCD19/huBCMA Mouse
Product Name
huCD19/huBCMA Mouse
Product ID
C001993
Strain Name
C57BL/6NCya-Cd19em3(hCD19)Tnfrsf17em1(hTNFRSF17)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “huCD19/huBCMA Mouse (Catalog C001993) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
TNFRSF17 & CD19
Gene Alias
BCM, BCMA, CD269, TNFRSF13A, B4, CVID3
NCBI ID
Chromosome
Chr 16 (Human), Chr 16 (Human)
MGI ID
Datasheet
Strain Description
CD19 is predominantly expressed throughout B-cell development and serves as a critical co-receptor for B-cell receptor (BCR) signal transduction, participating in B-cell development, activation, and differentiation [1]. The TNFRSF17 gene encodes B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily. BCMA is primarily expressed on mature B cells and plasma cells and acts as a key regulator for maintaining plasma cell survival, antibody secretion, and humoral immunity [2-3].
The huCD19/huBCMA(TNFRSF17) mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630). These two targets cover the critical stages of B-cell development and plasma cell maturation, respectively, together forming an important regulatory network for B-cell immune responses. This model can be used to study the mechanisms of B-cell development, differentiation, and humoral immunity regulation, as well as B-cell-related autoimmune diseases and malignancies such as systemic lupus erythematosus (SLE) and multiple myeloma (MM). It is also suitable for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of anti-CD19 and anti-BCMA dual-target drugs, CAR-T cell therapies, bispecific antibodies, and combination treatment strategies, providing an ideal preclinical research platform for the development of innovative therapies for B-cell-related diseases.
Reference
Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012 Nov 29;1(1):36.
Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125.
Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32(4):287–305.
Strain Strategy
The huCD19/huBCMA mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630).
Figure 1. Gene editing strategy of huCD19 mice. The sequences from the start codon to partial intron 4 of the mouse Cd19 gene were replaced with the sequences from the start codon to partial intron 4 of the human CD19 gene.
Figure 2. Gene editing strategy of huBCMA(TNFRSF17) mice. The mouse Tnfrsf17 endogenous extracellular domain was replaced with the human TNFRSF17 extracellular domain.
Application Area
Research on the regulatory mechanisms of B-cell development, differentiation, and humoral immunity;
Research on B-cell-related autoimmune diseases and malignancies such as systemic lupus erythematosus (SLE) and multiple myeloma (MM);
Research on the screening, pharmacodynamic evaluation, safety evaluation, and mechanism of action of dual-target drugs against CD19 and BCMA, CAR-T cell therapy, bispecific antibodies, and combination therapy strategies.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
